Published in Clin Cancer Res on December 06, 2010
Vaccine Therapy in Treating Patients With Malignant Glioma | NCT00068510
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res (2014) 1.73
Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res (2013) 1.68
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother (2012) 1.54
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol (2014) 1.53
The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res (2012) 1.20
Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res (2013) 1.20
Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18
Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS One (2012) 1.11
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res (2015) 1.09
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol (2014) 1.08
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther (2011) 1.07
Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One (2012) 1.07
Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res (2013) 1.06
Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother (2013) 1.06
Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res (2014) 1.05
AACR Cancer Progress Report 2014. Clin Cancer Res (2014) 1.05
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother (2012) 1.04
Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol (2013) 1.02
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med (2014) 1.00
Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res (2014) 0.99
Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med (2011) 0.98
Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol (2012) 0.98
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest (2015) 0.97
Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res (2011) 0.96
Current vaccine trials in glioblastoma: a review. J Immunol Res (2014) 0.96
The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev (2012) 0.95
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro Oncol (2015) 0.94
Immunotherapy for the treatment of glioblastoma. Cancer J (2012) 0.93
Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res (2014) 0.92
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res (2014) 0.90
PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight (2016) 0.90
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol (2012) 0.89
Glioblastoma: molecular pathways, stem cells and therapeutic targets. Cancers (Basel) (2015) 0.89
Overview of current immunotherapeutic strategies for glioma. Immunotherapy (2015) 0.89
Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease. Am J Transl Res (2014) 0.88
Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology (2015) 0.88
Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel) (2013) 0.88
Immune Evasion Strategies of Glioblastoma. Front Surg (2016) 0.88
The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol (2013) 0.87
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas. Clin Cancer Res (2012) 0.87
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control? Front Immunol (2014) 0.86
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics (2012) 0.85
Vaccination strategies for neuro-oncology. Neuro Oncol (2015) 0.85
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology (2015) 0.85
Cellular-based immunotherapies for patients with glioblastoma multiforme. Clin Dev Immunol (2012) 0.84
The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology (2013) 0.84
New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model. Clin Cancer Res (2013) 0.84
Getting by with a little help from the right CD4(+) T cells. Oncoimmunology (2013) 0.83
Differential glioma-associated tumor antigen expression profiles of human glioma cells grown in hypoxia. PLoS One (2012) 0.83
Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer (2014) 0.83
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer (2015) 0.83
Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. PLoS One (2015) 0.83
The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol (2017) 0.82
Characterization of the inflammatory response to solid cancer metastases in the human brain. Clin Exp Metastasis (2012) 0.82
Advances in the treatment of newly diagnosed glioblastoma. BMC Med (2015) 0.82
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer (2014) 0.82
Heat shock protein vaccines against glioblastoma: from bench to bedside. J Neurooncol (2015) 0.82
Improving vaccine efficacy against malignant glioma. Oncoimmunology (2016) 0.81
Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy (2013) 0.81
Immunotherapeutic advancements for glioblastoma. Front Oncol (2015) 0.81
Novel therapeutic targets in the brain tumor microenvironment. Oncotarget (2012) 0.81
HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma. Onco Targets Ther (2014) 0.80
The spectrum of vaccine therapies for patients with glioblastoma multiforme. Curr Treat Options Oncol (2012) 0.80
Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol (2012) 0.80
Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Protein Cell (2014) 0.80
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol (2017) 0.79
The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumors. Front Oncol (2013) 0.79
Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol (2015) 0.79
Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics (2016) 0.79
Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Res (2013) 0.79
Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther (2016) 0.79
Immunomonitoring in glioma immunotherapy: current status and future perspectives. J Neurooncol (2015) 0.79
Eosinophils in glioblastoma biology. J Neuroinflammation (2012) 0.78
Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis. PLoS One (2014) 0.78
TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunol Res (2016) 0.78
Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives. Front Pediatr (2013) 0.78
Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res (2015) 0.78
Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) (2013) 0.78
Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol (2017) 0.77
Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther (2016) 0.77
Correlation analysis connects cancer subtypes. PLoS One (2013) 0.77
Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clin Immunol (2015) 0.77
Emerging immunotherapies for glioblastoma. Expert Opin Emerg Drugs (2016) 0.77
Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity. Am J Transl Res (2015) 0.76
A combinatorial radiographic phenotype may stratify patient survival and be associated with invasion and proliferation characteristics in glioblastoma. J Neurosurg (2015) 0.76
Ependymomas: development of immunotherapeutic strategies. Expert Rev Neurother (2013) 0.76
DCVax®-L--developed by Northwest Biotherapeutics. Hum Vaccin Immunother (2014) 0.76
VSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients. Am J Transl Res (2015) 0.76
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol (2014) 0.76
Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination. Oncoimmunology (2013) 0.76
Therapeutic vaccine for brain cancer succeeds using a unique approach. Biotechnol Healthc (2011) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene (2003) 3.83
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist (2009) 3.18
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene (2003) 3.13
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 2.89
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol (2006) 2.81
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res (2009) 2.42
Celsius: a community resource for Affymetrix microarray data. Genome Biol (2007) 2.38
Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 2.37
Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics (2008) 2.29
Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus (2006) 2.25
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res (2008) 2.12
Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res (2001) 2.11
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys (2008) 2.08
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res (2008) 2.04
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol (2006) 1.79
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res (2005) 1.76
Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med (2007) 1.64
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer (2003) 1.63
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res (2004) 1.57
Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med (2008) 1.48
Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother (2004) 1.48
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38
CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci (2010) 1.26
Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res (2007) 1.26
Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci (2008) 1.21
Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg (1981) 1.13
Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods (2003) 1.08
Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. Expert Rev Neurother (2006) 0.93
Outcome-based profiling of astrocytic tumours identifies prognostic gene expression signatures which link molecular and morphology-based pathology. Int J Oncol (2006) 0.82
Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature (2008) 26.78
Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science (2008) 20.68
Resolving individuals contributing trace amounts of DNA to highly complex mixtures using high-density SNP genotyping microarrays. PLoS Genet (2008) 20.38
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
BFAST: an alignment tool for large scale genome resequencing. PLoS One (2009) 7.48
Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet (2008) 7.13
Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics (2011) 5.45
DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med (2011) 4.98
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Gene connectivity, function, and sequence conservation: predictions from modular yeast co-expression networks. BMC Genomics (2006) 3.87
Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene (2003) 3.83
A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet (2010) 3.42
Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res (2006) 3.41
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med (2012) 3.18
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene (2003) 3.13
Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A (2006) 3.03
Mutations in a human ROBO gene disrupt hindbrain axon pathway crossing and morphogenesis. Science (2004) 3.01
U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet (2010) 2.99
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 2.89
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A (2009) 2.55
CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke (2011) 2.52
Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46
Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther (2003) 2.38
Celsius: a community resource for Affymetrix microarray data. Genome Biol (2007) 2.38
C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet (2007) 2.35
Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics (2008) 2.29
Evidence for sex-specific risk alleles in autism spectrum disorder. Am J Hum Genet (2004) 2.24
Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia. Nat Genet (2008) 2.24
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2010) 2.21
Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res (2006) 2.18
Detecting tissue-specific regulation of alternative splicing as a qualitative change in microarray data. Nucleic Acids Res (2004) 2.17
Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells (2009) 2.10
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys (2008) 2.08
Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med (2012) 2.08
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (2013) 2.00
Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience. Epilepsia (2009) 1.99
Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res (2008) 1.96
Local alignment of two-base encoded DNA sequence. BMC Bioinformatics (2009) 1.94
ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat Genet (2012) 1.93
Mutations in PYCR1 cause cutis laxa with progeroid features. Nat Genet (2009) 1.89
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab (2013) 1.86
Oxysterols are novel activators of the hedgehog signaling pathway in pluripotent mesenchymal cells. J Biol Chem (2007) 1.83
Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210. N Engl J Med (2010) 1.81
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res (2009) 1.79
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol (2006) 1.79
Family-based genome-wide association scan of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2010) 1.79
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov (2011) 1.77
Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol (2005) 1.74
SeqWare Query Engine: storing and searching sequence data in the cloud. BMC Bioinformatics (2010) 1.72
Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res (2013) 1.68
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol (2011) 1.67
Identification of EpCAM as the gene for congenital tufting enteropathy. Gastroenterology (2008) 1.65
Replication of autism linkage: fine-mapping peak at 17q21. Am J Hum Genet (2005) 1.65
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci (2004) 1.64
A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am J Hum Genet (2002) 1.63
Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet (2011) 1.63
Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. Nat Genet (2012) 1.61
Pontocerebellar hypoplasia type 1: clinical spectrum and relevance of EXOSC3 mutations. Neurology (2013) 1.61
Ciliary abnormalities due to defects in the retrograde transport protein DYNC2H1 in short-rib polydactyly syndrome. Am J Hum Genet (2009) 1.59
Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology (2008) 1.58
SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science (2013) 1.57
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56